Results of low- and high-dose-rate interstitial brachytherapy for T3 mobile tongue cancer. 2003

Naoya Kakimoto, and Takehiro Inoue, and Toshihiko Inoue, and Shumei Murakami, and Souhei Furukawa, and Ken Yoshida, and Yasuo Yoshioka, and Hideya Yamazaki, and Eiichi Tanaka, and Kimishige Shimizutani
Department of Oral and Maxillofacial Radiology, Division of Oral Developmental Biology, Osaka University Graduate School of Dentistry, 1-8 Yamadaoka, Suita, Osaka 565-0871, Japan.

OBJECTIVE To evaluate the treatment results of low-dose-rate (LDR) and high-dose-rate (HDR) interstitial brachytherapy (ISBT) for T3 mobile tongue cancer. METHODS Between 1974 and 1992, 61 patients with T3 mobile tongue cancer were treated with LDR ISBT using (192)Ir hairpins with or without single pins. In addition, between 1991 and 1999, 14 patients were treated with HDR ISBT. For nine patients treated with ISBT alone, the total dose was 59-94 Gy (median 72 Gy) within one week in LDR ISBT and 60 Gy/10 fractions/5 days in HDR ISBT. For 66 patients treated with a combination therapy of external beam radiotherapy (EBRT) and ISBT, the total dose was 12.5-60 Gy (median 30 Gy) of EBRT and 50-112 Gy (median 68 Gy) within 1 week in LDR ISBT or 32-60 Gy (median 48 Gy)/8-10 fractions/5-7 days in HDR ISBT. RESULTS The 2- and 3-year local control rates of all patients were both 68%. The 2- and 3-year local control rates of patients treated with LDR ISBT were both 67%, and those with HDR ISBT were both 71%. The local control rate of patients treated with HDR ISBT was similar to those with LDR ISBT. CONCLUSIONS ISBT for T3 mobile tongue cancer is effective and acceptable. The treatment result of HDR ISBT is almost similar to that of LDR ISBT for T3 mobile tongue cancer.

UI MeSH Term Description Entries
D007496 Iridium Radioisotopes Unstable isotopes of iridium that decay or disintegrate emitting radiation. Ir atoms with atomic weights 182-190, 192, and 194-198 are radioactive iridium isotopes. Radioisotopes, Iridium
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D011832 Radiation Injuries Harmful effects of non-experimental exposure to ionizing or non-ionizing radiation in VERTEBRATES. Radiation Sickness,Radiation Syndrome,Injuries, Radiation,Injury, Radiation,Radiation Injury,Radiation Sicknesses,Radiation Syndromes,Sickness, Radiation,Sicknesses, Radiation,Syndrome, Radiation,Syndromes, Radiation
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D001918 Brachytherapy A collective term for interstitial, intracavity, and surface radiotherapy. It uses small sealed or partly-sealed sources that may be placed on or near the body surface or within a natural body cavity or implanted directly into the tissues. Curietherapy,Implant Radiotherapy,Plaque Therapy, Radioisotope,Radioisotope Brachytherapy,Radiotherapy, Interstitial,Radiotherapy, Intracavity,Radiotherapy, Surface,Brachytherapy, Radioisotope,Interstitial Radiotherapy,Intracavity Radiotherapy,Radioisotope Plaque Therapy,Radiotherapy, Implant,Surface Radiotherapy,Therapy, Radioisotope Plaque
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D005260 Female Females

Related Publications

Naoya Kakimoto, and Takehiro Inoue, and Toshihiko Inoue, and Shumei Murakami, and Souhei Furukawa, and Ken Yoshida, and Yasuo Yoshioka, and Hideya Yamazaki, and Eiichi Tanaka, and Kimishige Shimizutani
March 2014, Journal of contemporary brachytherapy,
Naoya Kakimoto, and Takehiro Inoue, and Toshihiko Inoue, and Shumei Murakami, and Souhei Furukawa, and Ken Yoshida, and Yasuo Yoshioka, and Hideya Yamazaki, and Eiichi Tanaka, and Kimishige Shimizutani
January 2014, Journal of radiation research,
Naoya Kakimoto, and Takehiro Inoue, and Toshihiko Inoue, and Shumei Murakami, and Souhei Furukawa, and Ken Yoshida, and Yasuo Yoshioka, and Hideya Yamazaki, and Eiichi Tanaka, and Kimishige Shimizutani
May 2000, Gan to kagaku ryoho. Cancer & chemotherapy,
Naoya Kakimoto, and Takehiro Inoue, and Toshihiko Inoue, and Shumei Murakami, and Souhei Furukawa, and Ken Yoshida, and Yasuo Yoshioka, and Hideya Yamazaki, and Eiichi Tanaka, and Kimishige Shimizutani
May 2000, Gan to kagaku ryoho. Cancer & chemotherapy,
Naoya Kakimoto, and Takehiro Inoue, and Toshihiko Inoue, and Shumei Murakami, and Souhei Furukawa, and Ken Yoshida, and Yasuo Yoshioka, and Hideya Yamazaki, and Eiichi Tanaka, and Kimishige Shimizutani
November 2000, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics,
Naoya Kakimoto, and Takehiro Inoue, and Toshihiko Inoue, and Shumei Murakami, and Souhei Furukawa, and Ken Yoshida, and Yasuo Yoshioka, and Hideya Yamazaki, and Eiichi Tanaka, and Kimishige Shimizutani
January 1998, Clinical oncology (Royal College of Radiologists (Great Britain)),
Naoya Kakimoto, and Takehiro Inoue, and Toshihiko Inoue, and Shumei Murakami, and Souhei Furukawa, and Ken Yoshida, and Yasuo Yoshioka, and Hideya Yamazaki, and Eiichi Tanaka, and Kimishige Shimizutani
September 2001, International journal of radiation oncology, biology, physics,
Naoya Kakimoto, and Takehiro Inoue, and Toshihiko Inoue, and Shumei Murakami, and Souhei Furukawa, and Ken Yoshida, and Yasuo Yoshioka, and Hideya Yamazaki, and Eiichi Tanaka, and Kimishige Shimizutani
May 2000, Gan to kagaku ryoho. Cancer & chemotherapy,
Naoya Kakimoto, and Takehiro Inoue, and Toshihiko Inoue, and Shumei Murakami, and Souhei Furukawa, and Ken Yoshida, and Yasuo Yoshioka, and Hideya Yamazaki, and Eiichi Tanaka, and Kimishige Shimizutani
February 2018, Journal of contemporary brachytherapy,
Naoya Kakimoto, and Takehiro Inoue, and Toshihiko Inoue, and Shumei Murakami, and Souhei Furukawa, and Ken Yoshida, and Yasuo Yoshioka, and Hideya Yamazaki, and Eiichi Tanaka, and Kimishige Shimizutani
September 2022, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
Copied contents to your clipboard!